All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Orphan drug designation granted to DT2216 for the treatment of T-cell lymphoma
Bookmark this article
On March 14, 2022, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to DT2216, a compound based on antiapoptotic protein targeted degradation technology, for the treatment of T-cell lymphoma1.
DT2216 is a first-generation compound designed to induce degradation of BCL-XL, an anti-apoptotic protein involved in malignant cell survival.1,2. This agent is currently being evaluated in a phase I clinical trial involving patients with confirmed advanced or metastatic solid tumors and hematologic malignancies that are unresponsive to currently approved treatments1.
It is hoped that DT2216 can help to address a critical unmet need for patients diagnosed with this rare form of cancer.
- PR Newswire. Dialectic Therapeutics announces DT2216 has received orphan drug designation from the FDA for the treatment of T-cell lymphoma. https://www.prnewswire.com/news-releases/dialectic-therapeutics-announces-dt2216-has-received-orphan-drug-designation-from-the-fda-for-the-treatment-of-t-cell-lymphoma-301501813.html. Published Mar 14, 2022. Accessed Mar 15, 2022.
- Khan S, Zhang X, Lv D, et al, A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25(12):1938-1947. DOI 1038/s41591-019-0668-z
More about...
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
60 votes - 49 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox